Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Cardiovascular Disease in Special Populations ePosters Cardio-Oncology ESC Premium Access ESC Congress 2021 - The Digital Experience

ESC 365 is supported by

ESC 365 is supported by